Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$172.44 USD
+1.59 (0.93%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $172.55 +0.11 (0.06%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
For Quest Diagnostics Incorporated, the company has a dividend yield of 1.87% compared to the Medical - Outpatient and Home Healthcare industry's median yield of zero percent.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
DGX 172.44 +1.59(0.93%)
Will DGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
Other News for DGX
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene ...
Quest Diagnostics Inc (DGX) Unveils Advanced Genetic Test for Ataxia Using PacBio's PureTarget ...
Quest Diagnostics (DGX) Sees Price Target Reduced by Piper Sandler
Quest Diagnostics price target lowered by $10 at Piper Sandler, here's why
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity